Opinion|Videos|January 3, 2025
Improving CAR-T Availability and Accessibility: How Does the Earlier Use of CAR-T Impact Treatment Sequencing?
Panelists discuss how institutional challenges around chimeric antigen receptor T-cell therapy slot availability and waiting list management influence treatment sequencing decisions and affect subsequent therapy choices in earlier treatment lines for multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How does the issue of slot availability for chimeric antigen receptor (CAR) T-cell therapy, along with the waiting list, fit into the ongoing challenges faced at the institutional level?
- Dr Abdallah to ask Dr Mushtaq: If you choose to use CAR T-cell therapy in earlier lines of therapy, what might you do next and why?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Spotlighting the Top 10 FDA Oncology Approvals in 2025
2
What’s New in Hematology/Oncology? Discussing the 2025 ASH Annual Meeting
3
Ivosidenib Combo Shows Preliminary Activity in IDH1-Mutated AML
4
Nab-Sirolimus Regimens Show Promise in HR+/HER2-Negative Breast Cancer
5